Journal of Clinical Oncology,
Journal Year:
2018,
Volume and Issue:
36(7), P. 633 - 641
Published: Jan. 16, 2018
Purpose
Treatment
of
advanced
non-small-cell
lung
cancer
with
immune
checkpoint
inhibitors
(ICIs)
is
characterized
by
durable
responses
and
improved
survival
in
a
subset
patients.
Clinically
available
tools
to
optimize
use
ICIs
understand
the
molecular
determinants
response
are
needed.
Targeted
next-generation
sequencing
(NGS)
increasingly
routine,
but
its
role
identifying
predictors
not
known.
Methods
Detailed
clinical
annotation
data
were
collected
for
patients
treated
anti-programmed
death-1
or
death-ligand
1
[anti-programmed
cell
death
(PD)-1]
therapy
profiled
targeted
NGS
(MSK-IMPACT;
n
=
240).
Efficacy
was
assessed
Response
Evaluation
Criteria
Solid
Tumors
(RECIST)
version
1.1,
benefit
(DCB)
defined
as
partial
response/stable
disease
that
lasted
>
6
months.
Tumor
mutation
burden
(TMB),
fraction
copy
number-altered
genome,
gene
alterations
compared
among
DCB
no
(NDB).
Whole-exome
(WES)
performed
49
compare
quantification
TMB
versus
WES.
Results
Estimates
correlated
well
WES
(ρ
0.86;
P
<
.001).
greater
than
NDB
(
.006).
more
common,
progression-free
longer
at
increasing
thresholds
above
below
50th
percentile
(38.6%
v
25.1%;
.001;
hazard
ratio,
1.38;
.024).
The
genome
highest
those
NDB.
Variants
EGFR
STK11
associated
lack
benefit.
PD-L1
expression
independent
variables,
composite
plus
further
enriched
ICIs.
Conclusion
accurately
estimates
elevated
likelihood
did
correlate
expression;
both
variables
had
similar
predictive
capacity.
incorporation
into
multivariable
models
should
result
power.
Journal of the National Comprehensive Cancer Network,
Journal Year:
2019,
Volume and Issue:
17(5), P. 479 - 505
Published: May 1, 2019
The
NCCN
Guidelines
for
Prostate
Cancer
include
recommendations
regarding
diagnosis,
risk
stratification
and
workup,
treatment
options
localized
disease,
management
of
recurrent
advanced
disease
clinicians
who
treat
patients
with
prostate
cancer.
portions
the
guidelines
included
herein
focus
on
roles
germline
somatic
genetic
testing,
nomograms
tumor
multigene
molecular
androgen
deprivation
therapy,
secondary
hormonal
chemotherapy,
immunotherapy
in
Signal Transduction and Targeted Therapy,
Journal Year:
2020,
Volume and Issue:
5(1)
Published: March 20, 2020
Abstract
Colorectal
cancer
(CRC)
is
among
the
most
lethal
and
prevalent
malignancies
in
world
was
responsible
for
nearly
881,000
cancer-related
deaths
2018.
Surgery
chemotherapy
have
long
been
first
choices
patients.
However,
prognosis
of
CRC
has
never
satisfying,
especially
patients
with
metastatic
lesions.
Targeted
therapy
a
new
optional
approach
that
successfully
prolonged
overall
survival
Following
successes
anti-EGFR
(epidermal
growth
factor
receptor)
agent
cetuximab
anti-angiogenesis
bevacizumab,
agents
blocking
different
critical
pathways
as
well
immune
checkpoints
are
emerging
at
an
unprecedented
rate.
Guidelines
worldwide
currently
updating
recommended
targeted
drugs
on
basis
increasing
number
high-quality
clinical
trials.
This
review
provides
overview
existing
CRC-targeted
their
underlying
mechanisms,
discussion
limitations
future
trends.
Journal of Clinical Oncology,
Journal Year:
2018,
Volume and Issue:
36(7), P. 633 - 641
Published: Jan. 16, 2018
Purpose
Treatment
of
advanced
non-small-cell
lung
cancer
with
immune
checkpoint
inhibitors
(ICIs)
is
characterized
by
durable
responses
and
improved
survival
in
a
subset
patients.
Clinically
available
tools
to
optimize
use
ICIs
understand
the
molecular
determinants
response
are
needed.
Targeted
next-generation
sequencing
(NGS)
increasingly
routine,
but
its
role
identifying
predictors
not
known.
Methods
Detailed
clinical
annotation
data
were
collected
for
patients
treated
anti-programmed
death-1
or
death-ligand
1
[anti-programmed
cell
death
(PD)-1]
therapy
profiled
targeted
NGS
(MSK-IMPACT;
n
=
240).
Efficacy
was
assessed
Response
Evaluation
Criteria
Solid
Tumors
(RECIST)
version
1.1,
benefit
(DCB)
defined
as
partial
response/stable
disease
that
lasted
>
6
months.
Tumor
mutation
burden
(TMB),
fraction
copy
number-altered
genome,
gene
alterations
compared
among
DCB
no
(NDB).
Whole-exome
(WES)
performed
49
compare
quantification
TMB
versus
WES.
Results
Estimates
correlated
well
WES
(ρ
0.86;
P
<
.001).
greater
than
NDB
(
.006).
more
common,
progression-free
longer
at
increasing
thresholds
above
below
50th
percentile
(38.6%
v
25.1%;
.001;
hazard
ratio,
1.38;
.024).
The
genome
highest
those
NDB.
Variants
EGFR
STK11
associated
lack
benefit.
PD-L1
expression
independent
variables,
composite
plus
further
enriched
ICIs.
Conclusion
accurately
estimates
elevated
likelihood
did
correlate
expression;
both
variables
had
similar
predictive
capacity.
incorporation
into
multivariable
models
should
result
power.
